Table 1 Patients’ Characteristics
From: 18F-DCFPyL PET/CT in primary staging of prostate cancer
No. of patients | 133 | |
|---|---|---|
Mean Age (y) | 71 (range, 44–88) | |
Median PSA at scanning (ng/mL) | 25.0 (range, 0.3–3400) | |
PSA category (No. of patients) | ||
 < 10 | 31 | |
 10–19.9 | 20 | |
 20–49.9 | 48 | |
 50–99.9 | 12 | |
 > 100 | 19 | |
Gleason score (No. of patients) | ||
 6 | 9 | |
 7 | 28 | |
 8 | 38 | |
 9 | 47 | |
 10 | 6 | |
 Unknown | 5 | |
cT stage (No. of patients) | ||
 x | 6 | |
 1 | 9 | |
 2 | 43 | |
 3 | 64 | |
 4 | 11 | |
cN stage (No. of patients) | ||
 x | 117 | |
 0 | 10 | |
 1 | 6 | |
cM stage (No. of patients) | ||
 x | 118 | |
 0 | 11 | |
 1a | 1 | |
 1b | 3 | |
Risk on lymph node metastases categories (No. of patients) | MSKCC nomogram | ROACH formula |
 0–19.9 | 20 | 6 |
 20–39.9 | 21 | 47 |
 40–59.9 | 31 | 43 |
 60–79.9 | 22 | 11 |
 80–100 | 33 | 20 |
Relevant imaging before 18F-DCFPyL PET/CT | ||
 None | 92 | |
 99mTc-HDP BS + SPECT/CT | 22a | |
 18F-NaF PET/CT | 7 | |
 MRI | 9 | |
 CT | 2 | |
 18F-FDG PET/CT | 1 | |